Actively Recruiting
Molecular Detection of Advanced Neoplasia in Pancreatic Cysts
Led by Mayo Clinic · Updated on 2025-12-17
800
Participants Needed
1
Research Sites
659 weeks
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are trying to find out whether new tests ("biomarkers") of blood, stool, pancreas cyst fluid, or pancreas juice can be used to diagnose malignant or pre-malignant changes in pancreas cysts.
CONDITIONS
Official Title
Molecular Detection of Advanced Neoplasia in Pancreatic Cysts
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pancreatic cystic lesions meeting Fukuoka worrisome or Fukuoka high-risk criteris
- Patients with suspected cystic neoplasm of the pancreas
- Able to provide written informed consent
You will not qualify if you...
- Pregnant and/or nursing
- Incarceration
- Imaging showing possible pancreatic cancer
- Prior history of pancreatic cancer or pancreatic surgery
- History of receiving systemic chemotherapy or abdominal radiation within the last 5 years
- Previous therapy for a pancreatic cystic lesion
- History of pancreatic necrosis
- Diagnosis of cancer (other than non-melanoma skin cancer) within the last 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
I
IN-CYST Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here